Novocure's Late-Stage Trial For Tumor Treatment Misses Primary Endpoint

Dow Jones06-18

By Connor Hart

Novocure said a late-stage trial evaluating the earlier initiation of treatment for newly diagnosed glioblastoma didn't demonstrate a statistically significant improvement in overall survival. This was when compared with starting treatment during the subsequent maintenance phase of treatment.

The company said Thursday that initiating Tumor Treating Fields, or TTFields, therapy at the start of chemoradiation resulted in a median overall survival rate of 17.7 months, compared with a median overall survival rate of 17.5 months when initiated during the maintenance phase.

"The study did not meet its primary endpoint, but the results from (the trial) demonstrated the feasibility and safety of initiating Tumor Treating Fields therapy during chemoradiation," said Uri Weinberg, Novocure's chief medical and innovation officer.

Shares fell 11%, to $15.90, in premarket trading.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

June 18, 2026 07:38 ET (11:38 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2644881270?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-18 19:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2644881270","market":"fut","top_or_hot":-1,"title":"Novocure's Late-Stage Trial For Tumor Treatment Misses Primary Endpoint","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Novocure said a late-stage trial evaluating the earlier initiation of treatment for newly diagnosed glioblastoma didn't demonstrate a statistically significant improvement in overall survival. This was when compared with starting treatment during the subsequent maintenance phase of treatment. \n</p>\n<p>\n  The company said Thursday that initiating Tumor Treating Fields, or TTFields, therapy at the start of chemoradiation resulted in a median overall survival rate of 17.7 months, compared with a median overall survival rate of 17.5 months when initiated during the maintenance phase. \n</p>\n<p>\n  \"The study did not meet its primary endpoint, but the results from (the trial) demonstrated the feasibility and safety of initiating Tumor Treating Fields therapy during chemoradiation,\" said Uri Weinberg, Novocure's chief medical and innovation officer. \n</p>\n<p>\n  Shares fell 11%, to $15.90, in premarket trading. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 18, 2026 07:38 ET (11:38 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novocure's Late-Stage Trial For Tumor Treatment Misses Primary Endpoint</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovocure's Late-Stage Trial For Tumor Treatment Misses Primary Endpoint\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-06-18 19:38</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Novocure said a late-stage trial evaluating the earlier initiation of treatment for newly diagnosed glioblastoma didn't demonstrate a statistically significant improvement in overall survival. This was when compared with starting treatment during the subsequent maintenance phase of treatment. \n</p>\n<p>\n  The company said Thursday that initiating Tumor Treating Fields, or TTFields, therapy at the start of chemoradiation resulted in a median overall survival rate of 17.7 months, compared with a median overall survival rate of 17.5 months when initiated during the maintenance phase. \n</p>\n<p>\n  \"The study did not meet its primary endpoint, but the results from (the trial) demonstrated the feasibility and safety of initiating Tumor Treating Fields therapy during chemoradiation,\" said Uri Weinberg, Novocure's chief medical and innovation officer. \n</p>\n<p>\n  Shares fell 11%, to $15.90, in premarket trading. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 18, 2026 07:38 ET (11:38 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2644881270","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2644881270","pubTimestamp":1781782680,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Novocure said a late-stage trial evaluating the earlier initiation of treatment for newly diagnosed glioblastoma didn't demonstrate a statistically significant improvement in overall survival. This was when compared with starting treatment during the subsequent maintenance phase of treatment.The company said Thursday that initiating Tumor Treating Fields, or TTFields, therapy at the start of chemoradiation resulted in a median overall survival rate of 17.7 months, compared with a median overall survival rate of 17.5 months when initiated during the maintenance phase.\"The study did not meet its primary endpoint, but the results from  demonstrated the feasibility and safety of initiating Tumor Treating Fields therapy during chemoradiation,\" said Uri Weinberg, Novocure's chief medical and innovation officer.Shares fell 11%, to $15.90, in premarket trading.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","BK4548":"巴美列捷福持仓","BK4082":"医疗保健设备","NVCR":"NovoCure Limited","BK4588":"碎股"},"translate_title":"Novocure肿瘤治疗后期试验未达到主要终点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVCR":0.9},"content_text":"By Connor Hart \n\n\n \n\n\n  Novocure said a late-stage trial evaluating the earlier initiation of treatment for newly diagnosed glioblastoma didn't demonstrate a statistically significant improvement in overall survival. This was when compared with starting treatment during the subsequent maintenance phase of treatment. \n\n\n  The company said Thursday that initiating Tumor Treating Fields, or TTFields, therapy at the start of chemoradiation resulted in a median overall survival rate of 17.7 months, compared with a median overall survival rate of 17.5 months when initiated during the maintenance phase. \n\n\n  \"The study did not meet its primary endpoint, but the results from (the trial) demonstrated the feasibility and safety of initiating Tumor Treating Fields therapy during chemoradiation,\" said Uri Weinberg, Novocure's chief medical and innovation officer. \n\n\n  Shares fell 11%, to $15.90, in premarket trading. \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 18, 2026 07:38 ET (11:38 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2644881270","isCrawlerRequest":true}